Company news
Oncolys Biopharma, Inc. (TSE:4588) news
Every Oncolys Biopharma, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP]
August 7, 2026
Oncolys BioPharma Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer
June 8, 2026
Oncolys BioPharma : Non-consolidated Financial Results for the Three Months Ended March 31, 2026
May 8, 2026
Oncolys BioPharma : Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2025
February 8, 2026
Oncolys BioPharma : Non-consolidated Financial Results for the Nine Months Ended September 30, 2025
November 7, 2025
Oncolys BioPharma : Non-consolidated Financial Results for the Six Months Ended June 30, 2025
August 8, 2025
Oncolys BioPharma : Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2024
February 7, 2025
Oncolys BioPharma : Non-consolidated Financial Results for the Six Months Ended June 30, 2024
August 9, 2024
Oncolys BioPharma : Announcement of Investigator-Initiated Phase 2 Clinical Trial Agreement For Immunotherapy refractory Esophagogastric adenocarcinoma
December 19, 2023
Oncolys BioPharma : Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy
October 16, 2023
Oncolys BioPharma : Non-consolidated Financial Results for the Three Months Ended March 31, 2023
May 12, 2023
Oncolys BioPharma : Non-consolidated Financial Results for the Nine Months Ended September 30, 2022
November 4, 2022
Oncolys BioPharma : Announcement of Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (censavudine, TPN-101) in Patients with Progressive Supranuclear Pals
August 17, 2022
Oncolys BioPharma : Non-consolidated Financial Results for the Six Months Ended June 30, 2022
August 5, 2022
Oncolys BioPharma : Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2021
February 10, 2022
Oncolys BioPharma : Announcement of Enrollment of First Patient in Phase IIa study for OBP-601 (Censavudine, TPN-101) in patients with ALS and/or FTD
January 21, 2022
Oncolys BioPharma : First Patient Dosed in NRG Oncology Phase I Clinical Trial for Telomelysin(OBP-301)-Chemoradiation Combination Therapy for Esophageal Cancer Patients
December 7, 2021
Oncolys BioPharma : Announcement of Enrollment of First Patient in Phase IIa Clinical Trial of OBP-601 (Censavudine, TPN-101) in Patients with PSP
November 18, 2021
Non-consolidated Financial Results for the Nine Months Ended September 30, 2021 [Japanese GAAP]
November 5, 2021
Oncolys BioPharma : Announcement of FDA Clearance of Two IND Applications to Initiate Phase 2 Clinical Trials of OBP-601 (Censavudine, TPN-101)
August 15, 2021
Oncolys BioPharma : to partner with Thermo Fisher Scientific for viral vector development and GMP manufacturing of their proprietary oncolytic virus, OBP-301
August 4, 2021